AstraZeneca Expands Savings Programs, Caps Inhaler Costs at $35 Per Month

The savings programs for AstraZeneca’s entire US inhaled respiratory portfolio will be expanded to help make its inhalers more affordable for eligible patients.

Starting June 1, 2024, eligible patients will pay no more than $35 per month for the following AstraZeneca inhalers: Airsupra (albuterol and budesonide), Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol, Breztri Aerosphere (budesonide, glycopyrrolate, and formoterol fumarate) inhalation aerosol, and Symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol. 

The expanded savings program comes after AstraZeneca reduced the list price of Symbicort on January 1, 2024. In the press release, the Company also noted that it will continue to provide discounts and rebates to help patients gain access to its inhaled respiratory medications.

Pascal Soriot, CEO, AstraZeneca, said: “AstraZeneca’s expanded savings programs build on our longstanding commitment to addressing barriers to access and affordability for patients living with respiratory diseases to ultimately help patients lead healthier lives. We remain dedicated to addressing the need for affordability of our medicines, but the system is complex and we cannot do it alone. It is critical that Congress bring together key stakeholders to help reform the healthcare system so patients can afford the medicines they need, not just today, but for the future.”